Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Willow Biosciences Inc. (TSX:WLLW) (OTCQB:CANSF) released its third-quarter financial and operating results Monday, revealing it has ended the quarter in a strong financial position, with approximately $35.7 million in cash on hand.
Willow completed its first commercial-scale fermentation run of its first cannabinoid, CBG, in Q1 2021 and signed up its first multi-year commercial agreement with Cellular Goods in Q2 2021.
During the remainder of 2021, Willow plans to continue to optimize its commercial process for CBG, supply products to customers, seed commercial samples to new potential customers and build out a robust order book for 2022, which the company expects to be its first full year of commercial production and sales. CBG is a rare cannabinoid and Willow is at the forefront of developing that market.
It also plans to continue to advance the development of its portfolio of other cannabinoids to bring them forward to commercialization.
"We continued to make significant strides forward in the third quarter and are well positioned to be the global leader in biosynthetically produced cannabinoids," Trevor Peters, Willow's president and CEO stated. "From our vantage point, we can see the larger players in the consumer-packaged goods ecosystem becoming increasingly more bullish on the health and wellness aspects of the cannabis industry. It has been our view all along that these entities need an ultra-pure, sustainably sourced ingredient supply to meet their long-term demands, and Willow's technology platform enables their entrance into this space."
Price Action
Willow Biosciences’ shares closed Friday market session 9.19% higher at $0.42 per share.
Photo: Courtesy of Andre Taissin on Unsplash